Cag

Cag

Price range: $59.00 through $99.00

For research purposes only. Not for human or animal use & not FDA-approved. By purchasing, you confirm you are 21 or older and qualified researcher.

Quantity Price
4 - 5 $53.10
6 - 9 $49.56
10 + $44.25
Money Back Guarantee Guaranteed Quality Customer Support Fast Shipping
SKU: N/A Categories: , ,

Description

Cagrilintide

Research-Grade Amylin Analogue
Tagline: Appetite & Weight Regulation Research

Product Description

Cagrilintide is a long-acting amylin analogue designed for once-weekly administration in research models. It mimics the effects of endogenous amylin, a hormone co-secreted with insulin from pancreatic β-cells, and plays a key role in satiety signaling, gastric emptying regulation, and weight management.

Researchers use cagrilintide Peptide to investigate appetite control, energy balance, obesity treatment strategies, and combination therapies with GLP-1 receptor agonists.

For Laboratory and Scientific Research Use Only. Not for Human Consumption.

Why Researchers Choose Cagrilintide Peptide

  • Long-Acting Amylin Analogue: Engineered with prolonged half-life for sustained activity.

  • Appetite Suppression Studies: Potently reduces food intake in preclinical models.

  • Weight Regulation Research: Promotes negative energy balance and body fat reduction.

  • Combination Therapy Applications: Studied alongside semaglutide for additive metabolic effects.

  • Batch Verified: ≥98% purity, HPLC-tested for reproducibility.

Important Note

For laboratory and scientific research only. Not for human consumption, therapeutic, or diagnostic use.

Details

Chemical Formula C₁₇₇H₂₆₉N₄₇O₅₃S
Molecular Mass ~3791 Da
CAS Number 1419995-32-2
Form Lyophilized peptide powder
Shelf Life 24 months (lyophilized)
Handling Protect from light; avoid repeated freeze-thaw cycles
Intended Use For preclinical and in vitro research only
Storage -20 °C (dry powder), -80 °C (after reconstitution)

Research

Research Applications

Appetite & Satiety Studies

Cagrilintide reduces food intake by activating amylin receptors in the area postrema and nucleus tractus solitarius [1].

Weight Management Research

Shown to induce dose-dependent weight loss and fat mass reduction in rodent and primate models [2].

Gastric Emptying Regulation

Delays gastric emptying, contributing to improved postprandial glucose control [3].

Combination Therapy with GLP-1 Analogues

Co-administered with semaglutide for additive effects on weight reduction and appetite suppression [4].

References

  1. Gabery S et al. (2020). Cagrilintide, a Long-Acting Amylin Analogue: CNS Target Engagement. Diabetes Obes Metab.
    https://insight.jci.org/articles/view/133429/sd/1

  2. Nauck MA et al. (2021). Weight-Loss Effects of Cagrilintide in Obesity Research. Lancet.
    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2821%2901751-7/fulltext

  3. Hay DL et al. (2015). Amylin Receptor Pharmacology and Gastric Emptying. Br J Pharmacol.
    https://docslib.org/doc/978634/amylin-pharmacology-physiology-and-clinical-potential

  4. Friedrichsen M et al. (2021). Cagrilintide Plus Semaglutide: Combination Therapy Research. Lancet.
    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2821%2900944-2/fulltext

Mechanism of Action

Mechanism of Action (How Cagrilintide Works)

  • Amylin Receptor Agonism: Binds to calcitonin receptor/RAMP complexes in the brainstem, activating satiety signaling [Gabery 2020].

  • Food Intake Suppression: Reduces meal size and frequency via CNS-mediated anorectic pathways [Nauck 2021].

  • Delayed Gastric Emptying: Slows gastric motility, improving postprandial glucose handling [Hay 2015].

  • Weight Loss Promotion: Induces negative energy balance by lowering caloric intake and enhancing energy expenditure [Nauck 2021].

  • Additive with GLP-1 RAs: Complements GLP-1 receptor agonist effects, resulting in greater weight loss when combined [Friedrichsen 2021].

References

  1. Gabery S et al. (2020). Cagrilintide, a Long-Acting Amylin Analogue: CNS Target Engagement. Diabetes Obes Metab.
    https://insight.jci.org/articles/view/133429/sd/1

  2. Nauck MA et al. (2021). Weight-Loss Effects of Cagrilintide in Obesity Research. Lancet.
    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2821%2901751-7/fulltext

  3. Hay DL et al. (2015). Amylin Receptor Pharmacology and Gastric Emptying. Br J Pharmacol.
    https://docslib.org/doc/978634/amylin-pharmacology-physiology-and-clinical-potential

  4. Friedrichsen M et al. (2021). Cagrilintide Plus Semaglutide: Combination Therapy Research. Lancet.
    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2821%2900944-2/fulltext

Certificate of Authenticity

Related products

  • KLOW - 80mg
  • TB-500
  • CJC-1295 (No DAC)
  • GLOW - 70mg